glp 1 agonist overdose A North Carolina woman was hospitalized for days after overdosing on a GLP-1 weight-loss injection prescribed online, as new data shows a nearly 1,500% surge in GLP-1–related overdoses nationwide Glucagon-Like Peptide-1 (GLP-1) Agonists: Decreasing

GLP-1 Market Report Scope : Segmentation of GLP-1 Market - GLP-1 Market by Type of Molecule - Biologic Peptide GLP-1 Agonists Small-Molecule Non-Peptide GLP-1 Agonists GLP-1 Market by Active Compound Used - Semaglutide Tirzepatide Dulaglutide Liraglutide Lixisenatide Exenatide Orforglipron Retatrutide Survodutide Other Active Compounds GLP-1 Market by Type of GLP-1 Agonist Drugs - Long-acting GLP-1 Agonist Short-acting GLP-1 Agonist GLP-1 Market by Type of Agonist - Single agonist Dual agonist Tri-agonist GLP-1 Market by Route of Administration- Oral Parenteral GLP-1 Market by Target Indication- Alzheimers Disease Non-Alcoholic Steatohepatitis Obesity Sleep Apnea Type 2 Diabetes GLP-1 Market By Dosing Frequency- Daily Weekly Monthly or Extended-Interval GLP-1 Market By Delivery System- Disposable Pre-filled Pen Auto-Injector Pre-filled Syringe Oral Tablet / Capsule GLP-1 Market By Payer- Retail Pharmacy Commercial Insurance Retail Pharmacy Government (Medicare / Medicaid) Specialty / Mail-Order Pharmacy Self-Pay GLP-1 Market by Region- North America- The US Canada Mexico Europe- Germany The UK France Italy Spain Rest of Europe Asia-Pacific- China Japan India South Korea Southeast Asia Rest of Asia Pacific Latin America- Brazil Argentina Rest of Latin America Middle East & Africa- GCC Countries South Africa Rest of the Middle East and Africa Research Design and Approach This study employed a multi-step, mixed-method research approach that integrates: Secondary research Primary research Data triangulation Hybrid top-down and bottom-up modelling Forecasting and scenario analysis This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market

doi: 10.1002/dmrr.3353 12 VermaSMcMurrayJJV

In December, the FDA declared that tirzepatide, the other popular GLP-1 drug, was no longer in shortage

Early and late complications of bariatric operation

Healthcare professionals can follow updates through organizations such as the American Diabetes Association and ongoing FDA communications regarding biosimilar development pathways